MANNKIND CORP (MNKD) Current Ratio
- Current ratio · latest quarter: Value 1.72×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.72× | Current assets / current liabilities. $245.71M ÷ $142.90M ≈ 1.72× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 245.71M USD | Assets, Current |
| Current obligations | 142.90M USD | Liabilities, Current |
| Cash and equivalents | 52.93M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 43.21M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 44.42M USD | Inventory, Net |
| Payables | 11.04M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $245.71M | $142.90M | $52.93M | (m) | $43.21M | $44.42M | $11.04M | (m) | 1.72× |
| 2026-03-31 | $251.16M | $134.56M | $52.83M | (m) | $28.14M | $49.17M | $16.14M | (m) | 1.87× |
| 2025-12-31 | $291.58M | $171.03M | $74.88M | (m) | $38.37M | $35.31M | $9.03M | (m) | 1.70× |
| 2025-09-30 | $358.84M | $109.13M | $127.39M | (m) | $17.38M | $26.97M | $7.27M | (m) | 3.29× |
| 2025-06-30 | $279.03M | $111.83M | $57.01M | (m) | $27.14M | $28.49M | $10.26M | (m) | 2.50× |
| 2025-03-31 | $273.74M | $115.94M | $47.31M | (m) | $28.90M | $28.89M | $5.04M | (m) | 2.36× |
| 2024-12-31 | $268.31M | $81.84M | $46.34M | (m) | $11.80M | $27.89M | $6.79M | (m) | 3.28× |
| 2024-09-30 | $327.66M | $72.10M | $62.37M | (m) | $18.18M | $26.66M | $6.44M | (m) | 4.54× |
| 2024-06-30 | $325.94M | $80.01M | $96.64M | (m) | $23.35M | $24.75M | $9.56M | (m) | 4.07× |
| 2024-03-31 | $383.10M | $99.90M | $193.27M | (m) | $19.91M | $26.44M | $7.15M | (m) | 3.84× |
| 2023-12-31 | $373.39M | $104.13M | $238.48M | (m) | $14.90M | $28.55M | $9.58M | (m) | 3.59× |
| 2023-09-30 | $225.57M | $96.37M | $83.02M | (m) | $21.82M | $27.12M | $16.75M | (m) | 2.34× |
| 2023-06-30 | $230.23M | $96.97M | $86.18M | (m) | $27.79M | $25.29M | $17.13M | (m) | 2.37× |
| 2023-03-31 | $223.30M | $81.85M | $85.87M | (m) | $19.71M | $22.00M | $13.89M | (m) | 2.73× |
| 2022-12-31 | $234.90M | $67.30M | $69.77M | (m) | $16.80M | $21.77M | $11.05M | (m) | 3.49× |
| 2022-09-30 | $218.38M | $59.60M | $54.31M | (m) | $23.49M | $18.27M | $9.87M | (m) | 3.66× |
| 2022-06-30 | $193.48M | $59.56M | $35.51M | (m) | $15.03M | $20.57M | $7.82M | (m) | 3.25× |
| 2022-03-31 | $184.26M | $53.49M | $67.24M | (m) | $9.82M | $8.04M | $8.70M | (m) | 3.44× |
| 2021-12-31 | $219.49M | $48.35M | $124.18M | (m) | $4.74M | $7.15M | $6.96M | (m) | 4.54× |
| 2021-09-30 | $159.21M | $50.03M | $51.74M | (m) | $9.45M | $7.48M | $9.53M | (m) | 3.18× |
| 2021-06-30 | $179.90M | $60.43M | $62.52M | (m) | $6.30M | $7.48M | $7.49M | (m) | 2.98× |
| 2021-03-31 | $288.34M | $73.12M | $247.83M | (m) | $3.57M | $5.05M | $6.71M | (m) | 3.94× |
| 2020-12-31 | $79.48M | $73.70M | $67.00M | (m) | $4.22M | $4.97M | $5.58M | (m) | 1.08× |
| 2020-09-30 | $66.35M | $106.12M | $52.40M | (m) | $4.13M | $4.88M | $5.80M | $45.38M | 0.63× |
| 2020-06-30 | $72.58M | $67.94M | $63.22M | (m) | $3.37M | $3.82M | $5.82M | (m) | 1.07× |
| 2020-03-31 | $49.35M | $68.25M | $38.87M | (m) | $5.03M | $3.23M | $6.73M | (m) | 0.72× |
| 2019-12-31 | $60.76M | $65.62M | $29.91M | (m) | $3.51M | $4.16M | $4.79M | (m) | 0.93× |
| 2019-09-30 | $61.74M | $64.29M | $30.17M | (m) | $4.09M | $3.69M | $11.66M | (m) | 0.96× |
| 2019-06-30 | $49.83M | $76.98M | $7.97M | (m) | $4.97M | $3.96M | $7.53M | (m) | 0.65× |
| 2019-03-31 | $69.69M | $77.87M | $34.53M | (m) | $3.76M | $3.72M | $6.98M | (m) | 0.90× |
| 2018-12-31 | $81.85M | $75.24M | $71.16M | (m) | $4.02M | $3.60M | $5.38M | (m) | 1.09× |
| 2018-09-30 | $19.52M | $59.63M | $10.45M | (m) | $2.75M | $2.79M | $5.82M | (m) | 0.33× |
| 2018-06-30 | $35.80M | $74.90M | $26.18M | (m) | $2.85M | $3.68M | $9.24M | (m) | 0.48× |
| 2018-03-31 | $35.03M | $80.67M | $26.71M | (m) | $1.55M | $3.89M | $4.98M | (m) | 0.43× |
| 2017-12-31 | $57.22M | $87.60M | $43.95M | (m) | $2.79M | $2.66M | $6.98M | (m) | 0.65× |
| 2017-09-30 | $28.63M | $91.47M | $20.09M | (m) | $1.80M | $3.13M | $5.28M | (m) | 0.31× |
| 2017-06-30 | $50.93M | $85.87M | $43.38M | (m) | $1.31M | $3.17M | $6.54M | (m) | 0.59× |
| 2017-03-31 | $56.09M | $93.05M | $47.98M | (m) | $438.00K | $3.70M | $1.52M | (m) | 0.60× |
| 2016-12-31 | $77.49M | $92.05M | $22.89M | (m) | $302.00K | $2.33M | $3.26M | (m) | 0.84× |
| 2016-09-30 | $48.60M | $105.83M | $35.53M | (m) | $3.14M | $5.12M | $5.09M | (m) | 0.46× |
| 2016-06-30 | $90.76M | $289.71M | $63.73M | (m) | (m) | $2.87M | $2.85M | (m) | 0.31× |
| 2016-03-31 | $44.14M | $249.21M | $27.65M | (m) | $144.00K | (m) | $582.00K | (m) | 0.18× |
| 2015-12-31 | $76.65M | $268.32M | $59.07M | (m) | (m) | (m) | $15.60M | (m) | 0.29× |
| 2015-09-30 | $71.24M | $267.31M | $32.93M | (m) | $1.68M | $23.40M | $4.44M | (m) | 0.27× |
| 2015-06-30 | $145.83M | $342.25M | $107.19M | (m) | $4.75M | $19.82M | $5.19M | (m) | 0.43× |
| 2015-03-31 | $158.29M | $380.75M | $120.84M | (m) | $4.28M | $16.79M | $3.30M | (m) | 0.42× |
| 2014-12-31 | $201.15M | $403.35M | $120.84M | (m) | $50.44M | $9.67M | $7.39M | (m) | 0.50× |
| 2014-09-30 | $193.52M | $293.78M | $172.47M | (m) | (m) | (m) | $17.39M | (m) | 0.66× |
| 2014-06-30 | $44.91M | $119.23M | $41.21M | (m) | (m) | (m) | $5.09M | (m) | 0.38× |
| 2014-03-31 | $39.40M | $44.52M | $35.76M | (m) | (m) | (m) | $3.64M | (m) | 0.89× |
| 2013-12-31 | $76.28M | $127.79M | $70.79M | (m) | (m) | (m) | $3.86M | (m) | 0.60× |
| 2013-09-30 | $99.33M | $217.17M | $93.80M | (m) | (m) | (m) | $7.79M | (m) | 0.46× |
| 2013-06-30 | $32.16M | $266.78M | $28.53M | (m) | (m) | (m) | $5.42M | (m) | 0.12× |
| 2013-03-31 | $32.28M | $264.21M | $28.00M | (m) | (m) | (m) | $3.60M | (m) | 0.12× |
| 2012-12-31 | $66.81M | $144.78M | $61.84M | (m) | (m) | (m) | $4.55M | (m) | 0.46× |
| 2012-09-30 | $23.20M | $51.76M | $1.76M | $350.00K | (m) | (m) | $3.17M | (m) | 0.45× |
| 2012-06-30 | $50.34M | $55.44M | $31.64M | $350.00K | (m) | (m) | $5.82M | (m) | 0.91× |
| 2012-03-31 | $59.71M | $34.41M | $56.35M | $350.00K | (m) | (m) | $2.66M | (m) | 1.74× |
| 2011-12-31 | $5.82M | $25.36M | $2.68M | (m) | (m) | (m) | $4.62M | (m) | 0.23× |
| 2011-09-30 | $27.02M | $17.31M | $22.79M | $513.00K | (m) | (m) | $1.60M | (m) | 1.56× |
| 2011-06-30 | $26.86M | $21.56M | $24.77M | $497.00K | (m) | (m) | $1.60M | (m) | 1.25× |
| 2010-12-31 | $73.95M | $18.13M | $66.06M | $4.37M | (m) | (m) | $3.29M | (m) | 4.08× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |